Latest Asx News

BCI Minerals reports robust progress in its Mardie Salt and Potash Project, achieving financial close on a $981 million debt facility and advancing construction beyond the halfway mark. The company maintains a strong focus on sustainability and safety as it targets first salt shipment in Q2 FY27.

Galan Lithium Limited has announced a substantial 150% increase in its Candelas Mineral Resource to 1.6 Mt LCE, lifting its total Hombre Muerto West resource to 9.5 Mt LCE and securing a spot among the world’s top 10 lithium projects.

White Cliff Minerals has secured all necessary permits to initiate drilling at its Rae Copper Project in Nunavut, targeting exceptionally high-grade copper zones identified in 2024. Drilling is set to commence in March 2025, focusing on the Hulk and Danvers prospects.

Holista Colltech Limited reports a notable financial recovery in 4QFY24, underpinned by strong cash inflows and a rebound in its Food Ingredients division, alongside a leadership change aimed at steering future growth.

Waratah Minerals has reported significant progress in its Spur Gold-Copper Project, extending gold zones with over 4,700 metres drilled in the December quarter. Strategic board appointments signal a new phase for the company as it positions itself for further exploration success.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

CurveBeam AI has reported a record quarter for HiRise™ device purchase orders, driven by a strategic expansion with Stryker in Australia and New Zealand. The company also advanced its FDA regulatory pathway for its BMD module, setting sights on mid-2025 submission.

Litchfield Minerals has confirmed a substantial expansion of the Oonagalabi base metal system, extending its geochemical footprint beyond 3km. The company is gearing up for an aggressive 2025 exploration campaign, including geophysical surveys and drilling, despite potential weather-related delays.

AUCyber Limited has recommended shareholders accept an increased cash takeover offer from 5G Networks Limited, raising the bid by 22.7% to 13.5 cents per share amid ongoing financial uncertainties.

Atlas Arteria reports solid traffic and toll revenue growth in Q4 2024, led by strong light vehicle volumes and strategic toll increases across its global portfolio.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.